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Background: Patients and physicians from three Latin American (LA) and six European countries were surveyed in
order to describe differences in journey to diagnosis, impact, and management of fibromyalgia (FM).
Methods: 900 patients (300 LA; 600 Europe) and 1824 physicians (604 LA; 1220 Europe) were surveyed between
October-December 2010 (LA) and February-April 2008 (Europe). Patients and physicians (GP or specialists)
completed separate questionnaires, on symptoms, impact, and FM management. Interviews were conducted in
local languages. Appropriate rating scales were used throughout. Data were analyzed using cross-tabulations and
descriptive statistics. Significance was determined at P < 0.05 (indicated by *).
Results: In LA versus Europe, patients reported having FM symptoms for longer (100.8 vs. 83.7* months), and taking
longer to be diagnosed (42.3 vs. 31.1* months). FM was characterized by multiple symptoms (11.2 vs. 6.9), but more
LA patients reported 14 common symptoms*, and rated pain higher on 11-point scale (8.0 vs. 7.2*). LA patients
were taking fewer medications (3.3 vs. 4.0). Patients from both regions found common symptoms very/extremely
disruptive to their quality of life, but symptoms impacted daily living and ability to work more significantly in LA.
Physicians (GPs or specialists) from LA more often considered problems sleeping*, difficulty concentrating*, anxiety*,
depression*, numbness/tingling*, and leg cramps* very/extremely disruptive vs. European physicians. Despite
headache, heightened sensitivity to touch, difficulty concentrating, and joint pain being experienced by ≥50% of
patients from both regions, <15% of PCPs or specialists considered these typical FM symptoms. Patients also
considered 12/14 symptoms more disruptive than PCPs or specialists in the same region. However, a higher
proportion of PCPs or specialists considered FM to have a strong/very strong impact on aspects of daily living vs.
patients within the same region.
Conclusions: Patient- and physician-rated disease perception and impact was often higher in LA than in Europe.
Patient and physician perspective concerning FM impact and disruption were often misaligned within the same
region. Our observations may be representative of cultural differences in stoicism, expression, beliefs, and attitudes
to pain perception and management. Better understanding of these complexities could help targeted educational/
training programs incorporating cultural differences, to improve chronic care.
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Fibromyalgia (FM) is a multi-factorial disease involving
physiological as well as psychological factors, and char-
acterized by widespread pain and muscle tenderness
accompanied by other comorbid symptoms [1,2]. Preva-
lence estimates vary, with up to 5% of women reported
to have FM from survey data in the US and across
Europe [2-4], but some lower estimates have been
presented from survey data of rheumatic diseases for
other regions, such as certain Latin American countries
[5-9]. Although the reasons for differences in prevalence
are ultimately unknown, differences among healthcare
practices, historical recognition of FM symptoms, and
dissemination of guidelines on diagnosis in different re-
gions of the world could be factors. In addition, referral
bias, whereby hospital-based data produce higher esti-
mates of disease prevalence than survey samples from
the general population, also contributes to variation in
the literature.
Guidelines for diagnosis and/or management of FM
have been published by recognized bodies, such as the
American College of Rheumatology (ACR) [1,10], and by
bodies outside of the US [11-13]. Despite these proto-
cols, FM is under-diagnosed and under-treated [14].
Physicians may diagnose patients by ruling out other
conditions that share some symptoms with FM, for
example chronic fatigue syndrome, rheumatoid arthritis,
and multiple sclerosis [15]. Local treatment practices
and diagnosis guidelines especially outside of the US and
the ACR may not be widely disseminated to physicians
who encounter patients with FM symptoms in their
everyday practice. As a result, diagnosis and treatment
can be delayed and efforts to improve recognition and
diagnosis are needed [14]. For some patients, satisfaction
with health status increases with a diagnosis [16], and
therefore earlier diagnosis and treatment may improve
treatment response and reduce the negative impact that
FM symptoms have on aspects of daily living [17-20]. FM
patients in some countries report frequent healthcare use
and work days lost compared with both non-FM subjects
and patients with other rheumatic conditions [17,21-23].
As a result of high healthcare use, studies from the US
and Europe have found that FM places a significant
economic burden on patients and healthcare systems
[24-26]. Hidden costs of disability and comorbidities
associated with FM likely increase the true burden of
FM even higher.
Despite the well-reported burden FM has on activities
of daily living, few data on the social and personal im-
pact of FM on patients from Latin American countries
have been published, and no data, to our knowledge,
have been published examining patient and physician
data from Latin America in comparison with other
countries that use different healthcare practices. Thisinternational survey of FM patients and physicians from
three Latin American countries and six European coun-
tries sought to examine differences in the perception
and management of FM, and social and occupational
aspects of FM between countries with different cultures
and economies: Latin America and Europe.
Methods
Data were collected between February-April 2008 in
Europe, and October-December 2010 in Latin America.
Surveyed physicians including primary care practitioners
(PCPs) and specialists were identified using proprietary
physician databases developed and maintained by research
agencies in each of the countries, lists of professional
physician associations, phone directories, and other
commercially available sample sources. “Physicians who
treated FM patients” or “FM-treating physicians” were de-
fined for this survey as physicians currently seeing or who
had seen at least one FM patient over the past 2 years. Pa-
tients had to have been diagnosed with FM by a physician
and they were identified by physicians who treated them
for FM. The recruiting physicians either participated in
the survey or were sampled specifically to recruit FM
patients, but did not complete the physician survey.
Except for patients from Brazil, patients and physicians
were compensated for completing the survey. Ethical
approval for this study was not required according to
regulations within the countries, at the time the surveys
were carried out.
Questionnaires
Patients and physicians completed different surveys. The
sponsor had no role during the conduct of the survey,
and the sponsor’s name did not appear on any of the
survey materials, nor was it mentioned to patients or
physicians during the survey. Therefore, the influence of
the sponsor on responses by physicians or patients
would be negligible. The English questionnaire was
translated into each language by an independent profes-
sional translation agency, and all translations were then
reviewed by a separate, independent translation agency.
The trained interviewer in healthcare research who
administered the questionnaire also reviewed the trans-
lations before collecting data. Patient interviews (face-
to-face or via telephone) averaged 25 minutes and were
conducted in local languages. Rating scales were used
throughout the survey.
Questions covered symptoms (a given list of 14 com-
mon symptoms), management, and impact of FM. Physi-
cians were also asked questions regarding their clinical
background. The scales used were: Disruption Scale
(Extremely disruptive, Very disruptive, Fairly disruptive,
Not very disruptive, Not at all disruptive; top two box
ratings = Extremely/Very disruptive); Agreement Scale
Table 1 Patient characteristics and FM symptoms














Average number of symptoms 11.2 6.9
Common symptoms experienceda
Chronic/widespread pain 92%* 62%
Problems sleeping 84%* 49%
Fatigue 88%* 46%
Headaches 84%* 61%
Facial pain 52%* 42%
Heightened sensitivity to touch 73%* 50%
Difficulty concentrating 78%* 52%
Numbness &/or tingling sensations 82%* 42%
Feelings of anxiety 79%* 28%
Feelings of depression 80%* 41%
Joint pain 89%* 59%
Stiffness 77%* 49%
Leg cramps 75%* 47%
Low back pain 83%* 55%
a 14 common symptoms were given.
* P < 0.05.
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disagree, Disagree somewhat, Disagree strongly; top two
box ratings = Agree strongly/Agree somewhat); Impact
Scale (Very strong impact, Strong impact, Moderate
impact, Slight impact, No impact; top two box ratings =
Very strong/Strong impact); Satisfaction Scale (Ex-
tremely satisfied, Very satisfied, Satisfied, Somewhat
satisfied, Not at all satisfied; top two box ratings =
Extremely satisfied/Very satisfied). Pain was rated on an
11-point numerical rating scale from 0 (“No pain”) to 10
(“Worst possible pain”). Copies of the surveys can be
found in the Additional file 1 and Additional file 2. All
scales had the equivalent option of decline to answer or
“Not known/Unsure”.
Statistical testing
Data were processed and quality assured. Data were ana-
lyzed using cross-tabulations and descriptive statistics;
no multivariate analysis was done. Significance was
determined at P < 0.05 using t test of column proportions.
Results
Patient’s perspective of FM
The study sample included 900 patients with a confirmed
diagnosis of FM according to ACR 1990 criteria [10]; 300
patients from Latin America (100 each from Mexico,
Venezuela, Brazil), and 600 from Europe (100 each from
UK, France, Germany, Italy, Spain, the Netherlands). The
majority of patients were female (93% LA; 85% Europe)
and aged 45–59 years (Table 1). Patients from Latin
America reported having FM symptoms for a significantly
longer time (100.8 vs. 83.7 months), and taking signifi-
cantly longer to be diagnosed (42.3 vs. 31.1 months), and
seeing more physicians to receive a diagnosis (5.4 vs. 4.0
physicians) compared with European patients, respectively
(P < 0.05 for all). In a typical month, fewer patients from
Latin America vs. Europe visited their physicians ≥2/
month (23% vs. 44%; P < 0.05).
FM was characterized by multiple symptoms in both
regions (LA: 11.2; Europe: 6.9), but a significantly higher
proportion of patients from Latin America vs. Europe, re-
spectively, reported common symptoms, including wide-
spread pain (92% vs. 62%), sleep problems (84% vs. 49%),
and fatigue (88% vs. 46%) (Table 1). Patients from Latin
America also rated their pain higher on an 11-point scale
vs. European patients (8.0 vs. 7.2). Patients from both
regions reported common FM symptoms as disruptive
(very/extremely), most commonly chronic/widespread
pain (LA vs. Europe: 86% vs. 78%), sleeping problems (80%
vs. 76%), and fatigue (80% vs. 75%) (Table 2). Patients from
Latin America more often reported that FM impacted
their ability to work and/or earn income than European
patients (Figure 1). Although fewer patients from Latin
America vs. Europe had been unemployed during the past12-months (LA: 33%, Europe: 42%); significantly more
patients from Latin America reported missing ≥40 days
of work due to FM (LA 24%; Europe: 3%). Patients
from Latin America also more often reported that FM
had a strong or very strong impact on aspects of daily
living than those from Europe, including on physical
mobility, motivation/drive, and their overall quality of
life (Figure 2A).
On average, patients from Latin America were taking
fewer medications (mean 3.3) than their European
counterparts (mean 4.0). When asked what treatments
they were currently using for FM, a similar proportion
of patients from both regions were taking analgesics
prescribed by physicians (LA: 66% vs. Europe: 70%), but
more patients from Europe were taking over-the-coun-
ter (OTC) pain relievers (LA: 27% vs. Europe: 44%: P <
0.05) (Figure 3). Patients from Latin America were less
likely than European patients to be using certain non-
pharmacological therapies for their FM, including relax-
ation techniques, biofeedback, and lifestyle changes
(Figure 3; P < 0.05 for all). Despite reporting use of
Table 2 Proportion of patients, PCPs, and specialists who report each symptom as “Very” or “Extremely” disruptive
Patients (%) PCPs (%)a Specialists (%) a












Chronic/Widespread pain 86%*‡ 78% 79% 78% 80% 79%
Problems sleeping 80%‡§ 76%‡§ 70%* 50% 69%* 55%
Fatigue 80%‡§ 75%‡§ 69% 67% 66% 69%
Headaches 69%‡§ 77%*‡§ 52%* 37% 45% 38%
Facial pain 59%‡§ 69%*‡§ 40%*† 24% 30% 27%
Heightened sensitivity to touch 61%‡§ 72%*‡§ 50%* 42% 48% 49%†
Difficulty concentrating 73%‡§ 73%‡§ 51%* 36% 50%* 39%
Numbness &/or tingling sensations 59%‡§ 62%‡§ 48%*† 25% 37%* 24%
Feelings of anxiety 75%*‡§ 64%‡§ 66%* 44% 64%* 47%
Feelings of depression 73% 77%‡§ 74%* 58% 73%* 62%
Joint pain 80%‡§ 76%‡§ 68%*† 55% 54% 53%
Stiffness 74%‡§ 74%‡§ 59%*† 39% 44% 39%
Leg cramps 67%*‡§ 60%‡§ 42%* 24% 35%* 27%
Low back pain 81%*‡§ 75%‡§ 59%*† 44% 50% 45%
a Base case: Physicians currently seeing or have seen patients with FM; * = P < 0.05 Europe vs. Latin America within group (Patient, PCP, Specialist); † P < 0.05 PCP
vs. specialist (within region); ‡ P < 0.05 patient vs. PCP (within region); § P < 0.05 patient vs. specialist (within region).
Clark et al. BMC Musculoskeletal Disorders 2013, 14:188 Page 4 of 11
http://www.biomedcentral.com/1471-2474/14/188various pharmacological and non-pharmacological ther-
apies for FM, only 30% of Latin American patients and
20% of European patients were satisfied (extremely/
very) with the ability of their treatments to relieve FM.
Physicians’ perspective of FM
The study sample included 1824 physicians (604 LA;
1220 Europe). PCPs were general/family practitioners
(LA 68%; Europe 100%) and the remainder were inter-
nists (LA 32%). Specialists were neurologists (LA: 29%;
Europe: 25%), psychiatrists (LA: 26%; Europe: 28%),
rheumatologists (LA: 27%; Europe: 26%), pain special-
ists/anaesthetists (LA: 16%; Europe 13%) and internists
(LA: 1%; Europe 2%). The majority of physicians had
been in practice for 11–30 years across regions, and
were treating ≤20 FM patients, regardless of speciality
(Table 3). PCPs saw more patients per month in each re-
gion than specialists, but, as would be expected, special-
ists in each region saw more FM patients than PCP. The
majority of physicians were aware of 1990 ACR criteria,
although the proportion of PCPs and specialists aware of
and working in practices that employed these criteria
was greater in Latin America than in Europe. Of 14
common symptoms, physicians similarly considered
chronic/widespread pain a typical symptom in Latin
America and in Europe, for PCPs (79% vs. 78%) and
specialists (80% vs. 79%), respectively. Both sets of physi-
cians from Latin America more often considered problems
sleeping, difficulty concentrating, anxiety, depression,
numbness/tingling, and leg cramps as disruptive (very/
extremely) vs. European physicians (Table 2). More than82% of PCPs and specialists from both regions indicated
that FM has a very strong or strong impact on patients
overall quality of life (Figure 2B and C). More PCPs from
Latin America than from Europe, however, considered FM
to have a very strong or strong impact on the individual
aspects of daily living (Figure 2B). Generally, similar pro-
portions of specialists from Latin America vs. Europe
rated impact on aspects of daily living (Figure 2C). When
compared within Europe, differences were recorded
between PCPs and specialists responses on the impact that
FM has aspects of daily living. Within Latin America the
responses from PCPs and specialists were similar for all
questions of daily living, except for the impact of FM on
sex life (Figure 2B and C).
Examining patient and physician perspectives
Chronic/widespread pain was a common symptom expe-
rienced by the majority of patients, and was considered
a typical FM symptom by the majority of physicians
(PCPs, and specialists, respectively) from both regions.
But, despite headache, heightened sensitivity to touch,
difficulty concentrating, and joint pain being experi-
enced by ≥50% of patients from both regions (Table 1),
<15% of PCPs or specialists considered these typical FM
symptoms (Table 4).
Chronic/widespread pain was considered disruptive
(very/extremely) by ≥78% of patients, PCPs and specialists
from both regions. Opinions on the disruption caused by
the majority of the other 14 listed FM symptoms were not
aligned among patients and PCPs or specialists within the
same region. For example, significantly more patients
Figure 1 Patient-reported impact of FM on work status and income. * = P < 0.05 comparison Europe vs. Latin America.
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least 12/14 symptoms more disruptive than PCPs or spe-
cialists within the same region (Table 2). The proportion
of patients and physicians (PCPs or specialists) within the
same region also differed on the impact caused by certainFigure 2 FM has a Very Strong/Strong impact on given aspects of pa
specialists a. a Base case: Physicians currently seeing or having seen patien
PCP, Specialist);† P < 0.05 PCP vs. specialist (within region); ‡ P < 0.05 patienFM symptoms on aspects of daily living but, interestingly,
a higher proportion of PCPs from Latin America, or spe-
cialists from both regions, considered FM had a strong or
very strong impact on aspects of daily living compared
with patients within the same region (Figure 2).tient’s life, as reported by (A) patients, (B) PCPs,a and (C)
ts with FM; * = P < 0.05 Europe vs. Latin America within group (Patient,
t vs. PCP (within region); § P < 0.05 patient vs. specialist (within region).
Figure 3 Pharmacological and non-pharmacological treatments that patients most frequently reported receiving to treat their FM.
* = P < 0.05 comparison Europe vs. Latin America. OTC, over the counter.
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A wealth of data exists on the burden of FM from individ-
ual countries, particularly from the United States. How-
ever data from within the Latin American region and









Have seen FM patients in past 2 years (including currently)




Are you aware of ACR 1990 criteria
Yes
Does your practice use ACR 1990 criteria to diagnose FM patients
Yes
* significant difference PCP vs. specialists within region.
a use base case = currently seeing/have seen FM patients in past 2 years.
† remainder declined to answer.has described the Latin American perspective of FM
alongside patients from a different region. This study
describes how FM is perceived and managed across differ-
ent healthcare settings using two regions with different
cultures and economies: Latin America and Europe.Europe Latin America
PCP Specialist PCP Specialist
N = 609 N = 611 N = 306 N = 298
21.2* 19.7 16.5 18.4*
103 (16.9%) 136 (22.3%) 123 (40.2%) 90 (30.2%)
434 (71.3%) 384 (62.8%) 155 (50.7%) 161 (54.0%)
71† (11.7%) 91 (14.9%) 28 (9.2%) 43† (14.4%)
473.1* 250.3 271.5* 191.8
60 (9.9%) 171 (28.0%) 77 (25.2%) 121 (40.6%)
153 (25.1%) 275 (45.0%) 144 (47.1%) 112 (37.6%)
392† (65.0%) 163† (26.7%) 81† (26.5%) 60† (20.1%)
n = 503 n = 495 n = 253 n = 254
rrently)a 20.0 61.0* 53.9 145.7*
401 (79.7%) 270 (54.5%) 169 (66.8%) 140 (55.1%)
72 (14.3%) 150 (30.3%) 57 (22.5%) 71 (28.0%)
28† (5.6%) 73† (14.7%) 26† (10.3%) 42† (16.5%)
249 (40.9%) 341 (55.8%) 221 (72.2%) 227 (76.2%)
151 (24.8%) 218 (35.7%) 165 (53.9%) 184 (61.7%)
Table 4 Typical symptoms that physicians look for when
diagnosing FM
Europe Latin America
Symptom † PCP Specialist PCP Specialist
N = 503 N = 495 N = 253 N = 254
Chronic/widespread
pain
55% 54% 68% 74%
Problems sleeping 1% 2% 4% 2%
Fatigue 7% 9% 5% 4%
Headaches 0 0 0 1%
Facial pain 0 1% 2% 0
Heightened sensitivity
to touch
14% 14% 7% 5%
Difficulty concentrating 1% 1% 0 0
Numbness &/or
tingling sensations
3% 2% 2% 1%
Feelings of anxiety 0 1% 0 0
Feelings of depression 4% 4% 2% 1%
Joint pain 7% 5% 3% 3%
Stiffness 3% 2% 2% 2%
Leg cramps 0 1% 1% 0
Low back pain 3% 1% 3% 3%
† 14 common symptoms were given. Base case = physicians currently seeing
or having seen patients with FM.
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FM is reported by patients and physicians to be a debilitat-
ing chronic/widespread pain condition, more common in
women, and which is characterized by multiple symptoms
that negatively impact daily living. The negative impact
FM had on patients and the disruption symptoms caused
to aspects of daily living are also broadly in line with
survey data from other regions [17,19,20,22], and reinforce
the high burden FM imparts on patients, regardless of
region of origin. Given the range of the data surveyed,
some divergence would be expected. Nevertheless, our
study presents many new observations in these popula-
tions, in addition to highlighting important differences,
particularly between the impact and disruption caused
by FM from a physician and patient viewpoint, within
the same region. Our data therefore highlight some
misalignment in perceptions of FM that need to be
addressed and warrant further investigation.
Our analysis extends individual reports from within
Latin America or Europe [5,7,19,29] to describe differ-
ences between patient and physician experiences regard-
ing how FM is diagnosed, perceived, and managed. For
example, patients from Latin America reported having
FM symptoms for significantly longer time, and taking
significantly longer to be diagnosed, and seeing more phy-
sicians to receive a diagnosis compared with European
patients. Studies from the United States indicate thatpatients often go 5 years before receiving a correct diagno-
sis of FM [14,17,30], suggesting that despite the differ-
ences in journey to diagnosis patients from both regions
herein were diagnosed relatively quickly (LA: 3.5 years;
Europe: 2.5 years). The time difference seen between
regions is representative of the work-up patients with FM
face when a diagnosis is unclear, particularly historically
when FM was less well defined and understood. For
example, pain or other symptoms (eg., fatigue, sleep
problems, depression, etc.) may have been treated by
physicians as separate conditions, or even disregarded if
they considered there to be a lack of medical evidence
for the pain [31]. These and similar issues are inherent
variables some patients face prior to receiving a con-
firmed diagnosis of FM [14]. Physicians, both PCPs and
specialists, were generally aware of the ACR 1990 diag-
nosis guidelines; however they were more widely known
and adopted in Latin America vs. European practices. This
could be representative of European practices adopting
European diagnosis or management practices that are
more locally disseminated to PCPs and specialists [32].
Evidence suggests that receiving an accurate diagnosis is
the first step to effective care and better outcomes for
patients [14]. As such, differences in time to diagnosis
in Latin America compared with Europe may have
influenced disease characteristics. For example, a higher
proportion of patients from Latin America reported
common symptoms, and reported symptoms as being
disruptive, than their European counterparts. Other fac-
tors influencing journey to diagnosis and FM experience
between regions should also be considered, including
patients being considered in different countries the
responsibility of primary care vs. rheumatology or other
specialist, which will in turn influence treatment prac-
tices as discussed in detail below.
Data were collected across different countries and
healthcare systems that have different treatment prac-
tices and cultures and some of the differences observed
in the FM experience may be reflective of these cultures
and practices. For example, although some data have
reported that clinical characteristics and patient per-
ceptions are broadly similar across different regions
[17,33,34], important ethnic, racial, and sociocultural
differences between populations in pain perception have
been noted [35-38]. Given the ethnic diversity of popula-
tions surveyed, these factors may well have influenced
responses provided, and account for some of the differ-
ences in disease experiences recorded, although the mag-
nitude of these influences remains unknown. Zborowski
and Zola published pioneering work investigating ethnic
and cultural differences in the experience of pain, includ-
ing attitudes and behavioral aspects that are generated
after pain, the differences in impact of the disease, and
what patients from different ethnic backgrounds do in
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this early work, numerous authors have published cultural
differences regarding stoicism, expression, beliefs, and
attitudes with regard to pain and pain perception. The
ways in which patients and healthcare providers interact
is also influenced by ethnicity, particularly when a
painful condition is present [41], and in certain ethnic
groups pain is reportedly undertreated [42]. For many
questions in the present study, patients from Latin
America rated responses significantly higher than in
Europe, which may be representative of the more “ex-
pressive” nature of patients from Latin American and
the more stoic European population [41]. How these
differences in journey to diagnosis and expression of
FM may ultimately impact FM prevalence, which is gen-
erally lower in Latin American countries compared with
Europe [3,5,9,29,43], would need further study. As such,
the generalizability of the data to other countries or
other FM patient populations cannot be assumed.
Patients from both regions reported using pharmaco-
logical and non-pharmacological approaches to manage
their FM symptoms, and differences noted between
regions provide some important insights into healthcare
practices between Europe and Latin America. For ex-
ample, aerobic exercise is helpful for some FM patients
[44,45] and it is somewhat surprising that less than 50%
of patients reported exercise therapy in either region.
This may suggest that when appropriate, physicians
should encourage their patients to participate in some
form of exercise. An interesting area of further study in
these regions would be to categorize the type and/or
schedule of exercise, e.g., giving subtypes of exercise
(gentle, aerobic, walking, etc.) may change the propor-
tion of patients responding. For example, a study com-
paring FM management in Germany vs. the US reported
that “aerobic exercise” was used by 32% of the US con-
sumers compared with 58% German consumers; how-
ever gentle exercise was much higher (64% vs 80%) [46].
Other non-pharmacological treatment options, such as
relaxation techniques, biofeedback, and lifestyle changes,
were more commonly used in Europe. Given differences
in economy for some Latin American vs. European
countries, these treatments may not be easily accessible
and/or reimbursed, and their utility and effectiveness is
therefore harder to demonstrate in Latin America. From
a pharmacological perspective, FM was managed by mul-
tiple medications, albeit fewer in Latin America than in
Europe, which as noted above, may have influenced
number and negative impact of FM symptoms in Latin
America vs. Europe. Physician treatment practices have
been shown to vary depending on ethnicity [42,47]. These
inherent variables may have influenced prescribing prac-
tices in Latin America vs. Europe, especially considering
fewer symptoms were experienced by patients in Europe.OTC medications were used by up to 70% of patients in
both regions, highlighting that patients may have been
self-managing their symptoms, in addition to, or instead
of their prescriptions. Although the specific OTC therap-
ies used were not captured and will have varied among
countries surveyed even within-region, over half of all
patients reported out-of-pocket costs in both regions,
albeit significantly more in patients from Latin America
than Europe. Although not quantified by actual costs, the
wider economic impact of FM was most notable in Latin
America, with almost half of employed patients missing
more than 40 days’ work in the past year. Efforts should
be made to help keep patients working, as long-time sick
leave has been found detrimental to long-term recovery
[48,49]. As a result, energy conservation, occupational
therapy, evaluation, and work adaptation are important
aspects of FM management [49,50] and our survey sug-
gests in particular that physicians in Latin America should
be made aware and help keep patients in work.
We report that many different types of physicians are
seeing FM patients in these two healthcare settings, pro-
bably due to the diverse range of symptoms that are
involved in the condition. Our study highlights that in
Europe more patients were seen in primary care by a
general practitioner, compared with 32% seen by inter-
nists for primary care in Latin America. A range of spe-
cialists were seeing FM patients in both regions. The
ability to conduct an efficient and accurate assessment and
diagnosis will depend on the physician’s background know-
ledge and training [51,52], and the differences in training
experiences between countries may have influenced pa-
tients’ journey to diagnosis, as discussed previously. For ex-
ample, ACR diagnosis criteria are used in many countries
outside of the United States, including most often in Latin
American countries and across some parts of Europe.
Regional knowledge of diagnosis guidelines will vary,
however. Recent advances in the understanding of the
pathophysiology of FM may not have extended to non-
specialists in primary care, and may also have differed
between regions as indicated by the differences in know-
ledge and adoption of the ACR criteria, for example. In
addition, updated ACR diagnosis criteria [1] and other
guidelines outside of the US [12,32] reflect that generalized
pain does not adequately characterize FM and a broader
assessment of pain, function, and psychosocial aspects may
aid in FM diagnosis and, ultimately, management. These
observations are supported by the symptoms experienced
by patients from both regions in the present survey.
Updated diagnosis guidelines were released by ACR in
May 2010, just prior to the Latin American survey. As a
result, these updated guidelines may have increased general
awareness of FM. Indeed, although pain was the principal
symptom in both regions, Latin American physicians more
often considered a wider range of typical FM symptoms as
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European counterparts, many of which are consistent with
the updated ACR diagnosis guidelines. With growing
acceptance and understanding of FM, there seems a need
to include focused education for physicians regarding FM,
starting ideally at medical school, to ensure all types of
physician have a basic understanding of the condition
when encountered. It is also paramount there is a better
understanding, particularly in non-specialists, of mecha-
nisms of chronic vs. acute pain in order to fully under-
stand the physiology of FM and other chronic pain
conditions. This is particularly important given the dif-
ferent approaches to management required for pain of
different origins, in addition to effective management of
comorbidities and the multi-factorial symptoms of FM
[53]. Enhancing educational initiatives in both countries
may help improve recognition, diagnosis, and patient
satisfaction with management in the longer term [54-56].
We also suggest that further efforts to implement struc-
tured treatment paradigms, incorporating pharmaco-
logical and non-pharmacological approaches for FM, may
likewise guide physicians and improve confidence in treat-
ment choices most appropriate for FM.
It is well known that a range of physicians encounter
patients with FM; however, few studies have commented
on how patients and physicians perceive FM differently
and furthermore how this is influenced by physician
type. Overall, FM symptoms were reported by patients
and physicians from both regions to be “Very” or “Ex-
tremely” disruptive, and having a negative impact on
many aspects of daily living. More physicians (PCPs or
specialists) from Latin America considered recognized
somatic symptoms of FM (per [1,10]), such as problems
sleeping, difficulty concentrating, depression, and numb-
ness/tingling, as disruptive (Very/Extremely) than their
European counterparts. Nevertheless, more Latin American
patients rated FM symptoms as disruptive than their
physicians. This suggests that although physicians in
Latin America are more aware of the disruption caused
by common FM symptoms than their European coun-
terparts, their perceptions still fall short of patients from
the same region. Despite these differences in opinions
on disruption of FM symptoms, interestingly within
Latin America, more physicians (PCPs or specialists)
rated that FM had a “Very strong” or “Strong” impact
on mood, sex life, and personal relationships than pa-
tients themselves, and furthermore matched patient’s re-
sponses to all other aspects of daily living. Within Europe,
more specialists likewise rated that FM had a very strong
or strong impact on some aspects of daily living than
European patients themselves, although responses from
patients and PCPs in Europe were generally better aligned.
Our observations suggest effort is needed to align patient’s
and physician’s perception of FM within these regions. Forexample, quality of life questionnaires alongside educa-
tional initiatives could help draw attention to which FM
symptoms are most disruptive and important to the
patient. These types of questionnaires are not widely used
in private practice, despite being translated into different
languages [57-60]. Collectively, our observations indicate
that there is still a long way to go concerning optimizing
management of FM, irrespective of ethnic background
and prescribing practices.
Our study should be interpreted in light of some
limitations. The World Health Organization (WHO) rec-
ognized and classified fibromyalgia in 1993, yet in some
countries doctors will have been unfamiliar with the
condition, diagnosis criteria and/or treatment practices.
In some countries included in our survey, no treatments
are specifically approved for the treatment of FM and
therefore management of patients both with prescrip-
tion products and off label where no products are
specifically available may have differed, particularly to
countries where clear treatment protocols for FM are
accepted and recommended. We sought to ensure that
the diagnosis of FM was not entirely dependent on the
patient’s recollection, by only including patients who
were diagnosed with FM by a physician according to
standard criteria [10]. FM is a clinical diagnosis and
previous research suggests physicians express difficul-
ties in diagnosis and managing FM, and confidence
varied depending on specialty [51]. Therefore whether
or not physicians were board-certified, and also if physi-
cians had experience of FM sufficient to make a differ-
ential diagnosis, are inherent variables for some of the
questions posed in the survey. We therefore ensured
that medical evidence was available for FM being
present, to limit the possibility of physicians dis-
regarding the pain condition due to lack of medical evi-
dence [31]. An important limitation of all opinion
research, to which this study is not an exception, is that
respondents may not perfectly recall their experiences
and feelings at the time of the survey, as respondents'
feelings, attitudes, and perceptions are subject to
change with time. The survey only provides a snapshot
of the respondents' experiences and does not seek to
address how these might have changed longitudinally.
Therefore, the observations should be considered
within the time-frame they were captured, which dif-
fered slightly between regions as noted above. Although
the numbers of respondents per country were the same,
data were collected from more European countries than
Latin American countries, increasing the diversity of
responders within the European dataset. Despite these
limitations, our study provides new insights into the
perceptions and management of FM patients in coun-
tries outside of the US, and identified some potential
areas for targeted improvement.
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Differences between FM characteristics, treatment prac-
tices, and opinions were noted by physicians and pa-
tients from Latin America and Europe and interestingly
patient- and physician-rated disease impact and percep-
tion was often higher in Latin America than in Europe.
Improved understanding of these complexities involved
in FM in different healthcare settings may help target
educational/training programs towards improving as-
pects of chronic care. As patient’s and physician’s per-
spectives concerning FM impact and disruption were
often misaligned within the same region, there is a clear
need to focus on understanding and ultimately improv-
ing these conflicting views in order to optimize chronic
care.
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